Neuberger Berman Group
MRTX

Neuberger Berman Group’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Neuberger Berman Group’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-7,225
Closed -$424K – 1955
2023
Q4 		$424K Sell
7,225
-19,638
-73% -$1.1M ﹤0.01% 1539
2023
Q3 		$1.17M Buy
26,863
+8,723
+48% +$311K ﹤0.01% 1211
2023
Q2 		$655K Buy
18,140
+1,734
+11% +$71.4K ﹤0.01% 1364
2023
Q1 		$610K Buy
16,406
+1,180
+8% +$53.1K ﹤0.01% 1399
2022
Q4 		$690K Sell
15,226
-3,128
-17% -$202K ﹤0.01% 1351
2022
Q3 		$1.28M Sell
18,354
-654
-3% -$48.4K ﹤0.01% 1196
2022
Q2 		$1.28M Buy
19,008
+1,746
+10% +$111K ﹤0.01% 1225
2022
Q1 		$1.42M Sell
17,262
-69,903
-80% -$7.15M ﹤0.01% 1270
2021
Q4 		$12.3M Buy
+87,165
New +$13.5M 0.01% 787
2021
Q3 		– Sell
-20,257
Closed -$3.27M – 1837
2021
Q2 		$3.27M Buy
20,257
+2,584
+15% +$415K ﹤0.01% 1066
2021
Q1 		$3.03M Buy
17,673
+434
+3% +$85.9K ﹤0.01% 1067
2020
Q4 		$3.79M Buy
+17,239
New +$3.73M ﹤0.01% 979
2019
Q2 		– Sell
-6,000
Closed -$440K – 1604
2019
Q1 		$440K Buy
+6,000
New +$408K ﹤0.01% 1287

Other funds holding MRTX

S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Neuberger Berman Group's MRTX Position: Q1 2024 in Review

Neuberger Berman Group sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 7,225 shares — an estimated $424K sold.

Neuberger Berman Group first reported a position in MRTX in Q1 2019 and held it in 13 quarters. The position peaked at $12.3M in Q4 2021. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

  • Neuberger Berman Group reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Neuberger Berman Group sold 7,225 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $424K.
  • Neuberger Berman Group first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2019 and held it in 13 quarters.
  • Neuberger Berman Group's Mirati Therapeutics, Inc. Common Stock position peaked at $12.3M in Q4 2021.
  • 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Neuberger Berman Group's 13F filing for Q1 2024, filed 13 May 2024.